ERBB2 and breast cancer: Building on the design of the PRO substudy in the VIRGO Metastatic Breast Cancer Registry, a US-based observational cohort study that followed more than 1200 women with primarily HER2-negative locally recurrent breast cancer or MBC[41], SystHERs is designed to provide a comprehensive PRO assessment with high patient adherence.